Association of Beta Blocker Use with Exercise Capacity in Participants with Heart Failure with Preserved Ejection Fraction: A Post-Hoc Analysis of the RELAX Trial

Patients with heart failure with preserved ejection fraction (HFpEF) often receive beta-blocker (BB) therapy for management of co-morbidities. However, the association of BB therapy with exercise capacity and health related quality-of-life (HRQL) in HFpEF is not well-studied. In this post-hoc analysis of the RELAX trial, which included chronic stable patients with HFpEF with peak exercise capacity assessment at baseline, 12 weeks, and 24 weeks follow-up, we evaluated the association of BB use with measures of exercise capacity (peak exercise oxygen uptake, VO2peak), anaerobic threshold (VO2AT), and HRQL (Minnesota Living with Heart Failure Questionnaire, MLHFQ).
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research